The North America diabetic retinopathy market is projected to grow from USD 4.25 billion in 2025 to around USD 7.47 billion by 2035, at a CAGR of 5.80%. Growth is driven by the rising prevalence of diabetes, increasing awareness of eye health, and advancements in retinal imaging and treatment technologies.

North America Diabetic Retinopathy Market Statical Scope

The contribution of eye care providers and ophthalmologists plays an integral role in treating the diabetic retinopathy condition in rural areas of the USA. The major factors contributing to the risk of retinopathy are disease duration, poor control of blood sugar levels over time, hypertension, kidney disease, high cholesterol levels, pregnancy, etc. According to the National Eye Institute, it is important to take medications prescribed by a doctor, reach and maintain a healthy weight, add physical activity to a day, kick the smoking habit, and control A1c, blood pressure, and cholesterol.

North America Diabetic Retinopathy Market Share, By Type, 2025 (%)

• Non-proliferative Diabetic Retinopathy (NPDR)- The non-proliferative diabetic retinopathy segment holds a major revenue share of 68%, owing to its higher prevalence in early-stage diabetic patients and increasing diagnosis through routine retinal screening programs.
• Proliferative Diabetic Retinopathy (PDR)- The proliferative diabetic retinopathy segment leads with a share of 32%, due to rising diabetes complications requiring advanced and intensive treatment interventions.

North America Diabetic Retinopathy Market Share, By Management, 2025 (%)

• Anti-VEGF- The anti-VEGF segment occupies a share of 58%, driven by strong clinical efficacy in preventing vision loss and its widespread adoption as a first-line treatment for diabetic retinopathy.
• Laser Surgery- The laser surgery segment accounts for a share of 20%, supported by its effectiveness in controlling abnormal blood vessel growth and long-standing use in retinal treatment.
• Intraocular Steroid Injection- The intraocular steroid injection segment drives the market with a share of 12%, accelerated by its role in reducing retinal inflammation and treating persistent macular edema.

Top Companies in the North America Diabetic Retinopathy Market

• Bayer AG
• AbbVie Inc.
• Novartis AG
• Oxurion NV.
• Sirnaomics
• Alimera Sciences
• Ampio Pharmaceuticals Inc.
• BCNPeptides
• Kowa Company, Ltd.
• Genentech, Inc.

Segments Covered in the Report

By Type

• Proliferative Diabetic Retinopathy
• Non-proliferative Diabetic Retinopathy

By Management

• Anti-VEGF
• Intraocular Steroid Injection
• Laser Surgery
• Vitrectomy